Norges Bank Takes $3.93 Million Position in LivaNova PLC (NASDAQ:LIVN)

Norges Bank bought a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, Holdings Channel.com reports. The firm bought 84,750 shares of the company’s stock, valued at approximately $3,925,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Nordea Investment Management AB lifted its holdings in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after acquiring an additional 12,470 shares during the period. Harbor Capital Advisors Inc. acquired a new position in LivaNova during the fourth quarter worth approximately $1,954,000. KBC Group NV raised its stake in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after purchasing an additional 56,580 shares during the period. Rhumbline Advisers boosted its holdings in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after purchasing an additional 899 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after buying an additional 1,424 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. The Goldman Sachs Group cut their target price on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Mizuho cut their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Barclays reduced their price objective on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Price Performance

LIVN stock opened at $34.14 on Friday. The firm has a market cap of $1.86 billion, a P/E ratio of 81.29 and a beta of 0.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $64.48. The stock has a 50-day simple moving average of $41.66 and a 200-day simple moving average of $47.44.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.